Explore research articles and continuing education for radiopharmaceutical therapies, including recorded content from SNMMI meetings, webinars, and more.

Continuing Education

SNMMI has compiled a comprehensive list of available educational activities related to radiopharmaceutical therapy. We encourage you to check frequently, as this content will continue to be updated monthly.

Clinical Practice | Dosimetry | General | Liver | NETs | Prostate | Thyroid

 

SNMMI 2021 Mid-Winter Meeting

SNMMI—the leader in radiopharmaceutical therapy education—is excited to share up-to-date overviews of key areas in a dedicated therapy track at the 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting. Leading experts in these areas will provide the insight you need to implement and prepare for current and future innovations in practice. In addition, the virtual platform will allow you to view sessions live as they happen, or on-demand following their live broadcast—giving you the flexibility to experience the entire meeting at the time of your choice.

Therapy track sessions include:

  • The Nuts and Bolts of IV Radiopharmaceutical Therapy Administration
  • Prostate Cancer PSMA Therapy
  • Updates on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications
  • Updates and Clinical Applications of PRRT for NET
  • Radioiodine Therapy for Differentiated Thyroid Cancer
Early-bird rates end Thursday, December 17. Register now and save.

SNMMI Therapeutics Conference

The two-and-a-half-day SNMMI Therapeutics Conference: Therapies, Theranostics, and Building Your Radionuclide Clinical Practice, explored the latest innovations in therapy, including acquiring the knowledge and resources to effectively deliver theranostics agents and the fundamental steps necessary to establish a nuclear medicine therapy program at your institution.

Third Targeted Radionuclide Therapy Conference   

SNMMI and the National Cancer Institute (NCI) held the Third Targeted Radionuclide Therapy Conference in December 2019. Invited attendees representing the major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives, held discussions on maximizing dose to tumor while sparing normal tissue, the current state of the science, state-of-the-art clinical trial design, and strategies for achieving response.

2018 Theranostics Consensus Conference

The SNMMI/National Cancer Institute (NCI) 2018 Theranostics Consensus Conference focused on key elements within this evolving field of nuclear medicine, including the current state of theranostic technology, challenges in trial design, and the training and requirements needed for administration and dose planning. With all stakeholders represented, participants had productive discussions on developing guidelines for efficient clinical trials, the drug approval process, and the best ways to collect necessary data for both timely and reasonable reimbursements and successful regulatory filings.

  • View Slides from the 2018 Theranostics Consensus Conference: Day 1 | Day 2
__

JNM

View the most recent content from The Journal of Nuclear Medicine (JNM) related to radionuclide therapy. 

Access JNM Therapy content.

JNMT

View the most recent content from the Journal of Nuclear Medicine Technology (JNMT) related to radionuclide therapy. 

Access JNMT Therapy content.

Featured Video


In the highly attended Theranostics: Regulatory Considerations for Product Development session at the SNMMI 2019 Annual Meeting in Anaheim, California, speakers examined clinical, nonclinical and CMC information needed for theranostics product development, including a discussion on regulatory perspectives of products combining an imaging modality with therapeutic radiopharmaceuticals.